Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma

High Grade Meningioma Clinical Trial

Official title: Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma

Status Active, not recruiting

Clinical Trial Summary

This research study is studying a drug as a possible treatment for High Grade Meningioma. The drug involved in this study is an immunotherapy drug called pembrolizumab

Clinical Trial Description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The FDA (the U.S. Food and Drug Administration) has not approved pembrolizumab for this specific disease but it has been approved for other uses. In this research study, the investigators are studying pembrolizumab in participants with meningioma. Research studies have shown that meningioma tumor cells express a gene called PD-L1. The investigators will be looking to determine whether the study drug may may stop meningioma tumors from growing. ;

Related Conditions & MeSH terms

• High Grade Meningioma
• Meningioma

• NCT number: NCT03279692
• Study type: Interventional
• Source: Massachusetts General Hospital
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: November 7, 2017
• Completion date: March 2025